Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers

MONMOUTH JUNCTION, N.J., Nov. 10, 2020 /PRNewswire/ —┬áTris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced the launch of a new website for patients and their caregivers.

ADHD impacts people of all ages and is one of the most common neurobehavioral disorders in children. Given the large impact of the disorder, there’s a need for ongoing education and access to resources that may help inform patients and caregivers about symptom management. Tris’ new website addresses this need within the ADHD community. With the launch of this new resource, patients and caregivers can learn more about ADHD and the multiple treatment options that are available from Tris. The website’s streamlined design and simple navigation make it easy for members of the

Read More